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Peroxisome proliferator-activated receptor γ (PPARγ) forms a heterodimeric DNA-binding complex with retinoid X receptors
(RXRs). It has been reported that the eﬀect of the PPAR agonist is reduced in hepatocyte RXR-deﬁcient mice. Therefore, it is
suggested that the endogenous RXR ligand is involved in the PPARγ agonist-induced anti-inﬂammatory eﬀect. However, the
participationoftheRXRligandinthePPARγ-inducedanti-inﬂammatoryeﬀectisunknown.Here,weinvestigatedtheinﬂuenceof
RXR antagonist on the anti-inﬂammatory eﬀect of PPARγ agonist pioglitazone in carrageenan test. In addition, we also examined
theinﬂuenceofPPARantagonistontheanti-inﬂammatoryeﬀectinducedbyRXRagonistNEt-3IP.TheRXRantagonistsuppressed
the antiedema eﬀect of PPARγ agonist. In addition, the anti-inﬂammatory eﬀe c to fR X Ra g o n i s tw a ss u p p r e s s e db yP P A R γ
antagonist. PPARγ agonist-induced anti-inﬂammatory eﬀects were reversed by the RXR antagonist. Thus, we showed that the
endogenous RXR ligand might contribute to the PPARγ agonist-induced anti-inﬂammatory eﬀect.
1.Introduction
Peroxisome proliferator-activated receptor (PPAR) is a fam-
ily comprising 3 diﬀerent isoforms: PPARα,P P A R γ,a n d
PPARδ. PPAR forms a heterodimeric DNA-binding complex
with the retinoid X receptor (RXR) and serves as a transcrip-
tional regulator of genes involved in lipid metabolism [1, 2].
In addition, it has been reported that PPARγ is expressed
in monocytes and macrophages; therefore, researchers have
shown much interest in the involvement of PPARγ in
inﬂammatory processes [3–6]. Studies have shown that the
PPARγ agonist is eﬀective in inﬂammatory models such
as intestinal inﬂammation [7], rheumatoid arthritis [8],
inﬂammatory lung disease [9], and allergic rhinitis [10].
These studies suggested that PPARγ agonist might be a new
drug for the treatment of inﬂammatory disease.
RXR is a member of the nuclear hormone receptor
superfamily and is activated by the endogenous agonist 9-cis
retinoic acid [11]. RXR functions as a dimer not only with
PPAR but also with other nuclear receptor partners such as
retinoid acid receptor (RAR), vitamin D receptor (VDR),
and liver X receptor (LXR) [2, 12]. Therefore, RXR is closely
linked to the function of such partners, and RXR agonists
synergistically control the function of RXR heterodimeric
partners [13]. Manzano et al. [14] have reported that in
human mesangial cells, 9-cis retinoic acid suppressed the
expression of vascular cell adhesion molecule (VCAM)-
1 and intercellular adhesion molecule (ICAM)-1 that was
induced by lipopolysaccharide (LPS), a bacterial endotoxin.
In addition, it has been reported that in microglial cells, 9-
cis retinoic acid reduced tumour necrosis factor-α (TNF-α)-
induced nitric oxide (NO) expression [15]. Therefore, it is
suggested that the RXR agonist exerts an anti-inﬂammatory
eﬀect. However, 9-cis retinoic acid activated not only RXR
but also RAR. Motomura et al. [16] have reported that the
suppressive eﬀect of 9-cis retinoic acid was not reversed by
RAR-speciﬁc antagonist. Moreover, the RAR-speciﬁc agonist
Ro 40-6055 did not show the inhibitory eﬀect shown by 9-cis2 PPAR Research
retinoic acid on the increase of NO and TNF-α levels
in Kupﬀer cells [16]. Therefore, it is suggested that the
inhibitory eﬀect of 9-cis retinoic acid does not depend on
the RAR/RXR signalling pathway but on another RXR het-
erodimersignallingpathway.Bensonetal.[17]ha v ereported
that the antiproliferative activity induced by the endogenous
PPAR agonist 15 deoxy-Δ12,14-PGJ2 was enhanced by the
endogenous RXR agonist 9-cis retinoic acid. In addition,
coactivation of the PPARγ agonist troglitazone and the RXR
agonist LG100268 resulted in additive eﬀects on glucose and
lipid metabolism in skeletal muscles [18]. Moreover, Diab et
al.[15]havereportedthatinmicroglialcells,15deoxy-Δ12,14-
PGJ2 and 9-cis retinoic acid individually weakly inhibited
NO production but together strongly and synergistically
inhibited NO production. Furthermore, it has been reported
that PPAR agonist did not inhibit carrageenan-induced paw
edema in hepatocyte-speciﬁc RXR-deﬁcient mice, whereas
PPAR agonist reduced carrageenan-induced paw edema in
wild-type mice [19]. Therefore, we hypothesized that the
endogenous RXR ligand is involved in the PPAR agonist-
induced anti-inﬂammatory eﬀect. However, it is not known
whether PPAR was activated by RXR in a ligand-dependent
manner.
Carrageenan-induced paw edema has been increasingly
used to test new anti-inﬂammatory drugs as well as to
study the mechanisms involved in inﬂammation. Therefore,
carrageenan-induced local inﬂammation is a useful model
to assess the contribution of mediators involved in vascular
changes associated with acute inﬂammation [20–23]. In
the present study, we examined the eﬀect of the RXR
antagonist on the anti-inﬂammatory eﬀect of the PPARγ
agonist pioglitazone in order to investigate the participation
of RXR in PPARγ activation. Moreover, we examined the
eﬀectsofPPARα,PP ARγ,andPP ARδ antagonistsontheanti-
inﬂammatory eﬀect induced by the RXR agonist NEt-3IP
with the aim of determining the PPAR subtype that is in-
volved in the RXR agonist-induced anti-inﬂammatory eﬀect.
2.MaterialsandMethods
2.1. Animals. Five-week-old male ICR mice (body weight,
23–28g) were purchased from Japan SLC, Shizuoka, Japan.
The animals were kept in an air-conditioned room at
a controlled temperature (24◦C ± 2◦C) and humidity
(55% ±15%). They were housed in plastic cages lined
with sawdust and kept under a light-dark cycle (lights on
from 0700–1900). Food and water were freely available,
except during test periods. All procedures involving animals
were conducted in accordance with the Guidelines for Ani-
mal Experiments at Okayama University Advanced Science
Research Center, and all procedures were licensed by the
AnimalResearchControlCommitteeofOkayamaUniversity.
2.2. Reagents. λ-Carrageenan (Wako, Osaka, Japan) was
dissolved in physiological saline. 6-[N-ethyl-N-(3-isoprop-
oxy-4-isopropylphenyl)-amino] nicotinic acid (NEt-3IP), 6-
[N-4-(triﬂuoromethyl) benzenesulfonyl-N-(5,5,8,8-tetram-
ethyl-5,6,7,8-tetrahydro-2-naphthyl) amino] nicotinic acid
(NS-4TF), and 3 -((2-ﬂuoro-4-(triﬂuoromethyl) benzami-
do) methyl)-4 -propoxybiphenyl-4-carboxylic acid (JKPL-
85) were synthesized at Okayama University [24, 25].
NEt-3IP and pioglitazone (Actos; Takeda Pharmaceutics,
Osaka, Japan) were suspended in 0.5% carboxymethyl-
cellulose solution. Bisphenol A diglycidyl ether (BADGE;
Sigma, St. Louis, Mo, USA), N-((2S)-2-(((1Z)-1-methyl-3-
oxo-3-(4-(triﬂuoromethyl) phenyl) prop-1-enyl) amino)-3-
(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl) ethoxy) phenyl)
propyl) propanamide (GW6471; Sigma), 2-chloro-5-nitro-
N-phenylbenzamide (GW9662; Sigma), and JKPL-85 were
dissolved in physiological saline containing 10% dimethyl-
sulphoxide. Actinomycin D (Sigma) was dissolved in physio-
logical saline containing 10% ethanol.
2.3. Drug Administration. Both pioglitazone (1, 3, and
1 0 m g / k g )a n dN E t - 3 I P( 1 ,3 ,a n d1 0 m g / k g )w e r eo r a l l y
administered 3h before carrageenan injection. NS-4TF (10
and 30μg/paw), GW6471 (10 and 30μg/paw), GW9662
(1, 3, and 10μg/paw), JKPL-85 (10 and 30μg/paw), and
actinomycin D (3 and 10μg/paw) were injected into the
subplantarregionofthehindpaw15minbeforecarrageenan
injection. BADGE (10 and 30mg/kg) was intraperitoneally
injected into mice 30min before the carrageenan injection.
2.4.MousePawEdema. Aftercarrageenaninjection,thehind
paw volume was measured at intervals of 1h for up to 3h.
The paw volume was determined using a plethysmometer
(TK-101; UNICOM, Chiba, Japan). The basal volume of
the hind paw was determined before the administration
of any drug. After determination of the basal volume, the
animals were divided into experimental groups in such a
way that the mean volumes of the diﬀerent groups were
similar. A 1% solution of λ-carrageenan dissolved in saline
(0.05mL/animal) was injected subcutaneously into the right
hind paw of each mouse. Paw edema was determined as the
diﬀerence in the paw volume before and after carrageenan
injection and was expressed as Δ paw volume.
2.5. Statistical Analysis. All data are presented as the mean
± standard error of the mean (S.E.M.). Statistical analysis
was performed using one-way analysis of variance (ANOVA)
withtheDunnett’stestorStudent’sunpairedt test.Whenthe
probability (P) value was less than 0.05, the diﬀerence was
considered to be signiﬁcant.
3. Results
3.1. Anti-Inﬂammatory Eﬀect of PPARγ Agonist. The PPARγ
agonist pioglitazone showed anti-inﬂammatory eﬀect in a
dose-dependent manner (Figure 1(a)). Oral administration
ofpioglitazoneatdosesof3and10mg/kgsigniﬁcantlyinhib-
ited carrageenan-induced paw edema as compared with that
of the control group. Pioglitazone (3mg/kg) signiﬁcantly
suppressed paw edema at 2 and 3h after carrageenan injec-
tion. Pioglitazone (10mg/kg) signiﬁcantly suppressed paw
edemaat1,2,and3haftercarrageenaninjection.Figure 1(b)
shows the eﬀect of the PPARγ antagonist GW9662 onPPAR Research 3
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Figure 1: Involvement of PPARγ on carrageenan-induced paw edema in mice. (a) Dose-dependence and time course of PPARγ agonist,
pioglitazone on carrageenan-induced paw edema in mice. Pioglitazone was orally administrated 3h before carrageenan injection at doses
of 1, 3, and 10mg/kg. The control group received 0.5% carboxymethylcellulose. (b) Eﬀect of PPARγ antagonist, GW9662 on pioglitazone
induced anti-inﬂammatory eﬀect. Pioglitazone was orally administrated 3h before carrageenan injection at a dose of 10mg/kg. GW9662
was injected 15min before carrageenan injection at doses of 1 and 3μg/paw. The vehicle group received physiological saline including 10%
dimethylsulphoxide. Each column and vertical bar represents the means ± S.E.M. (n = 7). ∗,∗∗: Signiﬁcantly diﬀerent from the control
group at P<0.05 and P<0.01, respectively, (Dunnett’s test). †,††: Signiﬁcantly diﬀerent from the vehicle group at P<0.05 and P<0.01,
respectively, (Dunnett’s test).
the anti-inﬂammatory eﬀect of pioglitazone. Intraplantar
injection of GW9662 at doses of 1 and 3μg/paw signiﬁcantly
reduced the anti-inﬂammatory eﬀect of pioglitazone.
3.2. Inﬂuence of RXR Antagonists on the Anti-Inﬂammatory
Eﬀect Induced by PPARγ Agonist. Figure 2 shows the inﬂu-
ence of NS-4TF on the anti-inﬂammatory eﬀect of pioglita-
zone.IntraplantarinjectionofNS-4TFatadoseof30μg/paw
signiﬁcantly reduced the anti-inﬂammatory eﬀect induced
by pioglitazone.
3.3. Anti-Inﬂammatory Eﬀect of RXR Agonist. The RXR
agonist NEt-3IP showed anti-inﬂammatory eﬀect in a dose-
dependent manner (Figure 3(a)). Oral administration of
NEt-3IP at doses of 3 and 10mg/kg signiﬁcantly inhibited
carrageenan-induced paw edema compared with that of
the control group. The control group received 0.5% car-
boxymethylcellulose solution. NEt-3IP (3mg/kg) signiﬁ-
cantly suppressed paw edema at 2 and 3h after carrageenan
injection. NEt-3IP (10mg/kg) signiﬁcantly suppressed paw
edemaat1,2,and3haftercarrageenaninjection.Figure 3(b)
shows the eﬀect of the RXR antagonist NS-4TF on the anti-
inﬂammatoryeﬀectofNEt-3IP.IntraplantarinjectionofNS-
4 T Fa tad o s eo f3 0 μg/paw signiﬁcantly reduced the anti-
inﬂammatory eﬀect of NEt-3IP.
3.4. Inﬂuence of PPAR Antagonists on the Anti-Inﬂammatory
Eﬀect Induced by RXR Agonist. Figure 4 shows the inﬂuence
of GW6471, BADGE, GW9662, and JKPL-85 on the anti-
inﬂammatory eﬀect induced by NEt-3IP. Intraperitoneal
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Figure 2: Inﬂuence of RXR antagonists on PPARγ agonist-induced
anti-inﬂammatory eﬀects. Pioglitazone was orally administrated 3h
before carrageenan injection at a dose of 10mg/kg. RXR antagonist,
NS-4TF was injected into subplantar 15min before carrageenan
injection at doses of 10 and 30μg/paw. The vehicle group received
physiological saline including 10% dimethylsulphoxide. Each col-
umn and vertical bar represents the means ± S.E.M. (n = 7).
∗∗: Signiﬁcantly diﬀerent from the control group at P<0.01
(Dunnett’s test). †: Signiﬁcantly diﬀerent from the vehicle group at
P<0.05 (Dunnett’s test).
injection of the PPARγ antagonist BADGE (30mg/kg) and
intraplantar injection of the PPARγ antagonist GW9662 (3
and 10μg/paw) signiﬁcantly reduced the anti-inﬂammatory4 PPAR Research
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Figure 3: Involvement of RXR on carrageenan-induced paw edema in mice. (a) Dose dependence and time course of RXR agonist, NEt-3IP on
carrageenan-induced paw edema in mice. NEt-3IP was orally administrated 3h before carrageenan injection at doses of 1, 3, and 10mg/kg.
The control group was received 0.5% carboxymethylcellulose. (b) Eﬀect of RXR antagonist, NS-4TF on NEt-3IP induced anti-inﬂammatory
eﬀect. NEt-3IP was orally administrated 3h before carrageenan injection at a dose of 10mg/kg. NS-4TF was injected 15min before
carrageenan injection at doses of 10 and 30μg/paw. The vehicle group received physiological saline including 10% dimethylsulphoxide.
Each column and vertical bar represents the means ± S.E.M. (n = 7). ∗,∗∗: Signiﬁcantly diﬀerent from the control group at P<0.05 and
P<0.01, respectively, (Dunnett’s test). ††: Signiﬁcantly diﬀerent from the vehicle group at P<0.01 (Dunnett’s test).
eﬀect induced by the RXR agonist. In contrast, intraplan-
tar injection of the PPARα antagonist GW6471 (10 and
30μg/paw) and the PPARδ antagonist JKPL-85 (10 and
30μg/paw) did not inhibit the anti-inﬂammatory eﬀect
induced by the RXR agonist. Both antagonists did not aﬀect
the paw edema at any time or concentration.
3.5. The Combination Eﬀect of RXR Agonist and PPARγ Ago-
nist on Carrageenan-Induced Paw Edema. Figure 5 shows
the combination eﬀect of pioglitazone and NEt-3IP on
carrageenan-induced paw edema. Coadministration of pio-
glitazone (1mg/kg) and NEt-3IP (1mg/kg) suppressed
carrageen-induced paw edema as compared to that of the
control group and the groups treated with pioglitazone
(1mg/kg) and NEt-3IP (1mg/kg).
3.6. Inﬂuence of Actinomycin D on the Anti-Inﬂammatory
Eﬀect Induced by RXR Agonist and PPARγ Agonist. Figures
6(a) and 6(b) show the inﬂuence of the RNA polymerase
inhibitor actinomycin D on the anti-inﬂammatory eﬀect of
pioglitazone and NEt-3IP. Intraplantar injection of actino-
mycin D at doses of 3 and 10μg/paw signiﬁcantly reduced
the anti-inﬂammatory eﬀect induced by PPARγ and RXR
agonist, respectively, compared with that in vehicle-treated
mice.
3.7. Inﬂuence of Reagents on Edema Induced by Carrageenan.
Figure 7 shows the inﬂuence of reagents on edema induced
by carrageenan. NS-4TF (30μg/paw), GW6471 (30μg/paw),
BADGE (30mg/kg), GW9662 (10μg/paw), and JKPL-85
(30μg/paw) have no inﬂuence on edema induced by car-
rageenan.
4. Discussion
In the present study, the PPARγ agonist pioglitazone signif-
icantly inhibited carrageenan-induced paw edema in mice,
andPPARγ antagonistsigniﬁcantlyinhibitedthissuppressive
eﬀect. In addition, the eﬀect of PPARγ agonist was prevented
by an inhibitor of RNA synthesis. Studies have reported
that rosiglitazone or pioglitazone showed anti-inﬂammatory
eﬀect via PPARγ in the carrageenan test [22, 26, 27]; these
ﬁndings are similar to the ﬁndings of our study. A previous
study found that the pioglitazone dose showing a signiﬁcant
anti-inﬂammatory eﬀect was less than that of another study
[28]. Therefore, it is suggested that that oral administration
of pioglitazone at 3h before carrageenan injection is a better
pathway of administration.
Wanetal.[29]havereportedthatfasting-inducedPPARα
activationwasstronglyinhibitedintheabsenceofhepatocyte
RXRα. In addition, Wan and Badr [19] have also reported
thatPPARαagonistdidnotinhibitcarrageenan-inducedpaw
edema in hepatocyte-speciﬁc RXRα-deﬁcient mice, whereas
PPARα agonist reduced carrageenan-induced paw edema
in wild-type mice. These results indicate that RXRα plays
a central role in PPARα-induced eﬀects. Therefore, we
hypothesize that the endogenous RXR ligand is involved in
PPAR activation. Consequently, we used an RXR antagonist
to ignore the inﬂuence of the endogenous RXR ligand. AsPPAR Research 5
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Figure 4: Inﬂuence of PPAR antagonists on RXR agonist and
PPARγ agonist-induced anti-inﬂammatory eﬀects.N E t - 3 I Pw a s
orally administrated 3h before carrageenan injection at a dose
of 10mg/kg. Nonselective PPAR antagonist, BADGE was injected
intraperitoneal 30min before carrageenan injection at doses of
10 and 30mg/kg. PPARα antagonist, GW6471 was injected into
subplantar 15min before carrageenan injection at doses of 10
and 30μg/paw. PPARγ antagonist, GW9662 was injected into
subplantar 15min before carrageenan injection at doses of 3 and
10μg/paw. PPARδ antagonist, JKPL-85was injected intosubplantar
15min before carrageenan injection at doses of 10 and 30μg/paw.
The vehicle group received physiological saline including 10%
dimethylsulphoxide. Each column and vertical bar represents the
means ± S.E.M. (n = 7). ∗∗: Signiﬁcantly diﬀerent from the control
group at P<0.01 (Dunnett’s test). †,††: Signiﬁcantly diﬀerent from
the vehicle group at P<0.05 and P<0.01, respectively (Dunnett’s
test).
described in the results section, the RXR antagonist signif-
icantly reduced the anti-inﬂammatory eﬀect of the PPARγ
agonist. Therefore, we suggest that the endogenous RXR
ligand may contribute to PPARγ activation. On the basis of
these ﬁndings, we speculate that the endogenous RXR ligand
and synthetic PPARγ agonist may function synergistically.
Additionally, we investigated the participation of PPAR
in the action of RXR. First, we evaluated the eﬀect of the
RXR agonist NEt-3IP on carrageenan-induced paw edema.
We found that the RXR agonist signiﬁcantly inhibited
carrageenan-induced paw edema in mice and that this eﬀect
was signiﬁcantly inhibited by both RXR antagonist and
actinomycin D, an inhibitor of RNA synthesis. RXR binds
the nuclear factor kappa B (NF-κB) components p50 and
p65 and also inhibits NF-κB transactivation [30]. Moreover,
Uchimura et al. [31] have showed that the synthetic RXR
agonist Ro47-5944 suppressed LPS-induced inducible nitric
oxide synthesis (iNOS) and TNF-α mRNA expression. In
addition, they also reported that Ro47-5944 suppressed the
promoter activity of NF-κB in RAW 264.7 cells. Studies have
reported that nuclear translocation of NF-κBw a sa c t i v a t e d
by carrageenan injection and that the expression of iNOS
and cyclooxigenase-2 (COX-2) observed in paw exudates
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
p
a
w
(
m
L
)
Pioglitazone
NEt-3IP
Carrageenan ++
+
+
+ +
+
+ − −
−−
∗∗
††
##
Δ
v
o
l
u
m
e
Figure 5:EﬀectofcombinationofRXRagonistandPPARγ agoniston
carrageenan-induced paw edema. Coadministration of pioglitazone
(1mg/kg) and NEt-3IP (1mg/kg), which showed no inhibition
each alone, suppressed carrageenan-induce paw edema compared
with control group, pioglitazone (1mg/kg) and NEt-3IP (1mg/kg)
treated group, respectively. The control group received 0.5%
carboxymethylcellulose solution. Each column and vertical bar
represents the means ± S.E.M. (n = 7). ∗∗: Signiﬁcantly diﬀerent
from the control group at P<0.01(Dunnett’s test). ††: Signiﬁcantly
diﬀerent from the pioglitazone treated group at P<0.01 (Dunnett’s
test). ##: Signiﬁcantly diﬀerent from the NEt-3IP treated group at
P<0.01 (Dunnett’s test).
was induced by carrageenan via NF-κB signalling [21, 23].
Therefore, in the present study, the anti-inﬂammatory eﬀect
of the RXR agonist may be caused via inhibition of NF-κB.
It has been reported that the PPAR/RXR heterodimer
can be activated by both RXR and PPAR agonists, either
independently or together to cause a synergistic activation
[32–34]. Therefore, it is thought that PPAR is involved
in the RXR-induced anti-inﬂammatory eﬀect. However,
it is unclear which subtypes of PPAR contribute to the
anti-inﬂammatory eﬀect of RXR agonist. Therefore, we
conﬁrmed the eﬀect of subtype-selective PPAR antagonist
on RXR agonist-induced anti-inﬂammatory eﬀect. Our data
showed that the PPARγ-selective antagonist, BADGE and
GW9662 signiﬁcantly inhibited the anti-inﬂammatory eﬀect
of the RXR agonist. In contrast, the PPARα-selective antag-
onist GW6471 and the PPARδ-selective antagonist JKPL-85
did not inhibit the suppressive eﬀect of the RXR agonist.
Theseresultsconﬁrmthattheanti-inﬂammatoryeﬀectofthe
RXR agonist occurs partially though PPARγ activation. In
addition, it is suggested that the endogenous PPARγ ligand
may contribute to RXR activation. However, the PPAR/RXR
heterodimer can be activated only by RXR agonists via
permissive mechanisms [35]. Furthermore, Ijpenberg et al.
[36] reported that the RXR/9-cis retinoic acid signalling
pathway could selectively bind to peroxisome proliferator
response element (PPRE) function and PPAR response
elementandinducetransactivation.Therefore,itisnecessary6 PPAR Research
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Figure 6: Inﬂuence of RNA polymerase inhibitor on PPARγ agonist and RXR agonist-induced anti-inﬂammatory eﬀects.( a )E ﬀect of RNA
polymerase inhibitor, actinomycin D on pioglitazone-induced anti-inﬂammatory eﬀect. Pioglitazone was orally administrated 3h before
carrageenan injection at a dose of 10mg/kg. Actinomycin D was injected 15min before carrageenan injection at doses of 3 and 10μg/paw.
The vehicle group received physiological saline including 10% dimethylsulphoxide. (b) Eﬀect of actinomycin D on NEt-3IP-induced
anti-inﬂammatory eﬀect. NEt-3IP was orally administrated 3h before carrageenan injection at a dose of 10mg/kg. Actinomycin D was
injected 15min before carrageenan injection at doses of 3 and 10μg/paw. The vehicle group received physiological saline including 10%
dimethylsulphoxide. Each column and vertical bar represents the means ± S.E.M. (n = 7). ∗∗: Signiﬁcantly diﬀerent from the control group
at P<0.01 (Dunnett’s test). †,††: Signiﬁcantly diﬀerent from the vehicle group at P<0.05 and P<0.01, respectively, (Dunnett’s test).
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Figure 7: Inﬂuence of reagents on edema induced by carrageenan.
BADGE was injected intraperitoneal 30min before carrageenan
injection at doses of 30mg/kg. NS-4TF (30μg/paw), GW6471
(30μg/paw), BADGE (30mg/kg), GW9662 (10μg/paw) and JKPL-
85 (30μg/paw), were injected into subplantar 15min before car-
rageenan injection. The vehicle group received physiological saline
including 10% dimethylsulphoxide. Each column and vertical bar
represents the means ± S.E.M. (n = 7).
to perform a more detailed in vitro investigation of these
functions.
In the case of the PPAR/RXR heterodimer, the binding
of the ligand of either receptor can activate the complex, yet
simultaneousbindingofbothligandsismorepotent[37,38].
This raises the question whether the coadministration of
PPAR and RXR ligands further enhances the anti-inﬂam-
matory eﬀect of either ligand in the carrageenan test.
Therefore, we studied whether the PPAR and RXR agon-
ists show synergistic function in the carrageenan test.
Administration of either pioglitazone (1mg/kg) or NEt-
3IP (1mg/kg) showed no eﬀect on carrageenan-induced
paw edema; however, the combined administration of
these 2 compounds resulted in signiﬁcant inhibition of
carrageenan-induced paw edema. Studies have reported the
combined eﬀect of PPARγ and RXR agonists on the chronic
inﬂammatory phase. Desreumaux et al. [39] also reported
that simultaneous treatment with the PPARγ agonist rosigli-
tazone and the RXR agonist LG101305 enhanced the levels of
TNF-α and interleukin (IL)-1β mRNA in the mouse colon.
Diab et al. [15] reported that 9-cis retinoic acid showed an
eﬀect on experimental autoimmune encephalomyelitis and
that this eﬀect was enhanced by the endogenous PPAR
agonist 15 deoxy-Δ12,14-PGJ2. Additionally, Burrage et al.
[40] reported that combinatorial treatment with rosiglita-
zone and the RXR agonist LG100268 inhibits IL-1β-induced
expression of MMP-1 more eﬀectively than treatment with
either individual compound. We showed that RXR and
PPARγ agonists could exert a synergistic anti-inﬂammatory
eﬀect during the acute-phase response in vivo.
Wang et al. [41] have reported that LPS, TNF-α,a n dI L -
1β causedRXRdownregulationinmousekidneycellsduring
theacute-phaseresponse.Inaddition,Haradaetal.[42]ha v e
reported that Th1 cytokine induced PPARγ downregulation
in human biliary cells. Moreover, it has been reported that
RXR and PPAR are suppressed in the liver and heart during
the acute-phase response [43]. Furthermore, Wan et al. [44]
reported that the expression levels of both PPAR and RXRPPAR Research 7
mRNA decrease in tissues, including the animal model of
liver inﬂammation. These ﬁndings indicate that each agonist
of PPARγ and RXR may be important for the action of
therapeutic drugs on inﬂammatory diseases.
In conclusion, we found that PPARγ agonist-induced
anti-inﬂammatory eﬀects were reversed by RXR antagonist.
Thus, we showed that the endogenous RXR ligand might
contribute to the PPARγ agonist-induced anti-inﬂammatory
eﬀect.
References
[1] S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Diﬀerential
expression and activation of a family of murine peroxisome
proliferator-activated receptors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 91, no.
15, pp. 7355–7359, 1994.
[2] D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear
receptor super-family: the second decade,” Cell, vol. 83, no. 6,
pp. 835–839, 1995.
[3] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K.
Glass, “The peroxisome proliferator-activated receptor-γ is a
negativeregulatorofmacrophageactivation,”Nature,vol.391,
no. 6662, pp. 79–82, 1998.
[4] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome
proliferator-activated receptors and inﬂammation,” Pharma-
cology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.
[5] J. Xu, S. W. Barger, and P. D. Drew, “The PPAR-γ agonist
15-deoxy-Δ12,14-prostaglandin J2 attenuates microglial pro-
duction of IL-12 family cytokines: potential relevance to
Alzheimer’s disease,” PPAR Research, vol. 2008, Article ID
349185, 2008.
[6] X. Y. Yang, L. H. Wang, and W. L. Farrar, “A role for PPARγ in
the regulation of cytokines in immune cells and cancer,” PPAR
Research, vol. 2008, Article ID 961753, 2008.
[7] A. Nakajima, K. Wada, H. Miki et al., “Endogenous PPARγ
mediates anti-inﬂammatory activity in murine ischemia-
reperfusion injury,” Gastroenterology, vol. 120, no. 2, pp. 460–
469, 2001.
[8] T. Shiojiri, K. Wada, A. Nakajima et al., “PPARγ ligands
inhibit nitrotyrosine formation and inﬂammatory mediator
expressions in adjuvant-induced rheumatoid arthritis mice,”
European Journal of Pharmacology, vol. 448, no. 2-3, pp. 231–
238, 2002.
[ 9 ]M .G .B e l v i s ia n dJ .A .M i t c h e l l ,“ T a r g e t i n gP P A Rr e c e p t o r si n
the airway for the treatment of inﬂammatory lung disease,”
British Journal of Pharmacology, vol. 158, no. 4, pp. 994–1003,
2009.
[ 1 0 ]E .J .J e o n ,S .K .L e e ,Y .S .P a r k ,D .H .K i m ,J .H .Y u m ,a n d
C. S. Park, “The eﬀects of Peroxisome Proliferator-Activated
Receptor-γ agonistonamurinemodelofexperimentalallergic
rhinitis,” Otolaryngology—Head and Neck Surgery, vol. 139,
no. 1, pp. 124–130, 2008.
[11] D. J. Mangelsdorf, U. Borgmeyer, R. A. Heyman et al., “Char-
acterizationofthreeRXRgenesthatmediatetheactionof9-cis
retinoic acid,” Genes and Development, vol. 6, no. 3, pp. 329–
344, 1992.
[ 1 2 ]M .K i z a k i ,Y .I k e d a ,R .T a n o s a k ie ta l . ,“ E ﬀects of novel
retinoic acid compound, 9-cis-retinoic acid, on proliferation,
diﬀerentiation, and expression of retinoic acid receptor-α and
retinoid X receptor-α RNA by HL-60 cells,” Blood, vol. 82, no.
12, pp. 3592–3599, 1993.
[13] D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers
and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.
[14] V. M. Manzano, J. C. S. Mu˜ noz, J. R. Jim´ enez et al., “Human
renal mesangial cells are a target for the anti-inﬂammatory
action of 9-cis retinoic acid,” British Journal of Pharmacology,
vol. 131, no. 8, pp. 1673–1683, 2000.
[15] A. Diab, R. Z. Hussain, A. E. Lovett-Racke, J. A. Chavis,
P. D. Drew, and M. K. Racke, “Ligands for the peroxisome
proliferator-activated receptor-γ and the retinoid X receptor
exert additive anti-inﬂammatory eﬀects on experimental
autoimmune encephalomyelitis,” Journal of Neuroimmunol-
ogy, vol. 148, no. 1-2, pp. 116–126, 2004.
[ 1 6 ]K .M o t o m u r a ,H .S a k a i ,H .I s o b e ,a n dH .N a w a t a ,“ E ﬀects
of retinoids on the production of tumour necrosis factor-α
and nitric oxide by lipopolysaccharide stimulated rat Kupﬀer
cells in vitro: evidence for participation of retinoid X receptor
signalling pathway,” Cell Biochemistry and Function, vol. 15,
no. 2, pp. 95–101, 1997.
[17] S. Benson, S. Padmanabhan, T. W. Kurtz, and H. A. Per-
shadsingh, “Ligands for the peroxisome proliferator-activated
receptor-γ and the retinoid X receptor-α exert synergistic
antiproliferative eﬀects on human coronary artery smooth
musclecells,”MolecularCellBiologyResearchCommunications,
vol. 3, no. 3, pp. 159–164, 2000.
[18] B. S. Cha, T. P. Ciaraldi, L. Carter et al., “Peroxisome
proliferator-activated receptor (PPAR)γ and retinoid Xrecep-
tor(RXR)agonistshavecomplementaryeﬀectsonglucoseand
lipid metabolism in human skeletal muscle,” Diabetologia, vol.
44, no. 4, pp. 444–452, 2001.
[19] Y. J. Wan and M. Z. Badr, “Inhibition of carrageenan-induced
cutaneous inﬂammation by PPAR agonists is dependent on
hepatocyte-speciﬁc retinoidXreceptorα,” PPARResearch,vol.
2006, Article ID 96341, pp. 1–6, 2006.
[20] S.Cuzzocrea,B.Pisano,L.Dugoetal.,“Rosiglitazone,aligand
of the peroxisome proliferator-activated receptor-γ,r e d u c e s
acute inﬂammation,” European Journal of Pharmacology, vol.
483, no. 1, pp. 79–93, 2004.
[21] I. Posadas, M. Bucci, F. Roviezzo et al., “Carrageenan-induced
mouse paw oedema is biphasic, age-weight dependent and
displays diﬀerential nitric oxide cyclooxygenase-2 expression,”
British Journal of Pharmacology, vol. 142, no. 2, pp. 331–338,
2004.
[22] G. C. Ramos, D. Fernandes, C. T. Char˜ a o ,D .G .S o u z a ,M .M .
Teixeira, and J. Assreuy, “Apoptotic mimicry: phosphatidylser-
ine liposomes reduce inﬂammation through activation of
peroxisome proliferator-activated receptors (PPARs) in vivo,”
British Journal of Pharmacology, vol. 151, no. 6, pp. 844–850,
2007.
[23] G. D’Agostino, G. La Rana, R. Russo et al., “Acute intrac-
erebroventricular administration of palmitoylethanolamide,
an endogenous peroxisome proliferator-activated receptor-α
agonist, modulates carrageenan-induced paw edema in mice,”
Journal of Pharmacology and Experimental Therapeutics, vol.
322, no. 3, pp. 1137–1143, 2007.
[24] K. Takamatsu, A. Takano, N. Yakushiji et al., “The ﬁrst
potent subtype-selective retinoid X receptor (RXR) agonist
possessing a 3-isopropoxy-4-isopropylphenylamino moiety,
NEt-3IP (RXRα/β-dual agonist),” ChemMedChem, vol. 3, no.
5, pp. 780–787, 2008.
[25] K. I. Morishita, N. Yakushiji, F. Ohsawa et al., “Replacing
alkyl sulfonamide with aromatic sulfonamide in sulfonamide-
type RXR agonists favors switch towards antagonist activity,”
Bioorganic and Medicinal Chemistry Letters,v o l .1 9 ,n o .3 ,p p .
1001–1003, 2009.8 PPAR Research
[26] B. K. Taylor, N. Dadia, C. B. Yang, S. Krishnan, and M. Badr,
“Peroxisome proliferator-activated receptor agonists inhibit
inﬂammatoryedemaand hyperalgesia,” Inﬂammation,vol.26,
no. 3, pp. 121–127, 2002.
[27] J. Youssef and M. Badr, “Role of peroxisome proliferator-
activated receptors in inﬂammation control,” Journal of Bio-
medicine and Biotechnology, vol. 2004, no. 3, pp. 156–166,
2004.
[28] A. C. Oliveira, C. M. Bertollo, L. T. Rocha, E. B. Nascimento,
K. A. Costa, and M. M. Coelho, “Antinociceptive and antiede-
matogenic activities of fenoﬁbrate, an agonist of PPAR α,
and pioglitazone, an agonist of PPAR γ,” European Journal of
Pharmacology, vol. 561, no. 1–3, pp. 194–201, 2007.
[29] Y. J. Wan, Y. Cai, W. Lungo et al., “Peroxisome proliferator-
activated receptor α-mediated pathways are altered in
hepatocyte-speciﬁc retinoid x receptor α-deﬁcient mice,”
Journal of Biological Chemistry, vol. 275, no. 36, pp. 28285–
28290, 2000.
[30] S. Y. Na, B. Y. Kang, S. W. Chung et al., “Retinoids inhibit
interleukin-12 production in macrophages through physical
associations of retinoid X receptor and NFκB,” Journal of
Biological Chemistry, vol. 274, no. 12, pp. 7674–7680, 1999.
[31] K. Uchimura, M. Nakamuta, M. Enjoji et al., “Activation
of retinoic X receptor and peroxisome proliferator-activated
receptor-γ inhibits nitric oxide and tumor necrosis factor-α
production in rat Kupﬀer cells,” Hepatology,v o l .3 3 ,n o .1 ,p p .
91–99, 2001.
[32] A.I.ShulmanandD.J.Mangelsdorf,“RetinoidXreceptorhet-
erodimersinthemetabolicsyndrome,”NewEnglandJournalof
Medicine, vol. 353, no. 6, pp. 604–615, 2005.
[33] L.S.ChanandR.A.Wells,“Cross-talkbetweenPPARsandthe
partnersofRXR:amolecularperspective,”PPARResearch,vol.
2009, Article ID 925309, 2009.
[34] M. Shimizu and H. Moriwaki, “Synergistic eﬀects of PPARγ
ligandsandretinoidsincancertreatment,”PPARResearch,vol.
2008, Article ID 181047, 2008.
[ 3 5 ] A .I .S h u l m a n ,C .L a r s o n ,D .J .M a n g e l s d o r f ,a n dR .
Ranganathan, “Structural determinants of allosteric ligand
activation in RXR heterodimers,” Cell, vol. 116, no. 3, pp. 417–
429, 2004.
[36] A. Ijpenberg, N. S. Tan, L. Gelman et al., “In vivo activation of
PPAR target genes by RXR homodimers,” EMBO Journal, vol.
23, no. 10, pp. 2083–2091, 2004.
[37] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in
health and disease,” Nature, vol. 405, no. 6785, pp. 421–424,
2000.
[38] Y. Wu and S. W. Guo, “Peroxisome proliferator-activated
receptor-γ and retinoid X receptor agonists synergistically
suppress proliferation of immortalized endometrial stromal
cells,”FertilityandSterility,vol.91,no.5,pp.2142–2147,2009.
[39] P. Desreumaux, L. Dubuquoy, S. Nutten et al., “Attenuation
of colon inﬂammation through activators of the retinoid X
receptor (RXR)/peroxisome proliferator-activated receptor γ
(PPARγ) heterodimer. A basis for new therapeutic strategies,”
Journal of Experimental Medicine, vol. 193, no. 7, pp. 827–838,
2001.
[40] P. S. Burrage, A. C. Schmucker, Y. Ren, M. B. Sporn, and
C. E. Brinckerhoﬀ, “Retinoid X receptor and peroxisome
proliferator-activated receptor-γ agonists cooperate to inhibit
matrix metalloproteinase gene expression,” Arthritis Research
and Therapy, vol. 10, no. 6, article R139, 2008.
[41] Y. Wang, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and
K. R. Feingold, “Downregulation of liver X receptor-α in
mouse kidney and HK-2 proximal tubular cells by LPS and
cytokines,” Journal of Lipid Research, vol. 46, no. 11, pp. 2377–
2387, 2005.
[42] K.Harada,K.Isse,T.Kamihira,S.Shimoda,andY.Nakanuma,
“Th1 cytokine-induced downregulation of PPARγ in human
biliary cells relates to cholangitis in primary biliary cirrhosis,”
Hepatology, vol. 41, no. 6, pp. 1329–1338, 2005.
[43] A. P. Beigneux, A. H. Moser, J. K. Shigenaga, C. Grunfeld,
and K. R. Feingold, “The acute phase response is associated
with retinoid X receptor repression in rodent liver,” Journal of
Biological Chemistry, vol. 275, no. 21, pp. 16390–16399, 2000.
[44] Y. J. Wan, D. An, Y. Cai et al., “Hepatocyte-speciﬁc mutation
establishes retinoid X receptor α as a heterodimeric integrator
of multiple physiological processes in the liver,” Molecular and
Cellular Biology, vol. 20, no. 12, pp. 4436–4444, 2000.